Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study

Clinical Therapeutics
Ophelia Q P YinHorst Schran

Abstract

Nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor approved for the treatment of patients who have imatinib-resistant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic or accelerated phase or who are unable to tolerate imatinib. Nilotinib is metabolized in the liver via oxidation and hydroxylation pathways, mediated primarily by the cytochrome P450 3A4 isozyme. Interpatient variability in systemic exposure to nilotinib has been reported to range from 32% to 64%. This study compared the pharmacokinetics of nilotinib in subjects with hepatic impairment and subjects with normal hepatic function. Hepatic impairment was classified as mild (Child-Pugh grade A), moderate (Child-Pugh grade B), or severe (Child-Pugh grade C). Healthy control subjects were matched with hepatically impaired subjects by age (+/-10 years) and body weight (+/-20%). All subjects received a single oral dose of nilotinib 200 mg under fasted conditions, and serial blood samples were collected at specific times up to 120 hours after dosing. Serum nilotinib concentrations were measured using a validated LC-MS/MS assay with a lower limit of quantification of 2.5 ng/mL. The pharmacokinetic parameters analyzed were C(max), T(max...Continue Reading

References

Aug 1, 1973·The British Journal of Surgery·R N PughR Williams
Oct 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·K K Chan, M Gibaldi
Feb 16, 2005·Cancer Cell·Ellen WeisbergJames D Griffin
Apr 20, 2005·Journal international de bioéthique = International journal of bioethics·UNKNOWN World Medical Association General Assembly
Jul 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mirna GolemovicMiloslav Beran
Sep 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maitreyee HazarikaRichard Pazdur

❮ Previous
Next ❯

Citations

Feb 25, 2011·Future Oncology·Paula Garland, Jane Apperley
Jun 18, 2014·Cancer Chemotherapy and Pharmacology·Narayana I NarasimhanDaryl Sonnichsen
Aug 6, 2010·Expert Opinion on Drug Metabolism & Toxicology·Derek R Duckett, Michael D Cameron
Sep 11, 2014·Journal of Clinical Pharmacology·Robert ShumakerMin Ren
Feb 13, 2016·Journal of Clinical Pharmacology·Linh NguyenSteven Lacy
Oct 20, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vito Spataro
Jul 28, 2018·Journal of Clinical Pharmacology·Peter N MorcosLi Yu
Sep 5, 2018·Journal of Clinical Pharmacology·Xianbin TianFlorence Hourcade-Potelleret
Sep 21, 2013·Therapeutic Drug Monitoring·Debra H JosephsRobert J Flanagan
Nov 9, 2017·Molecular Medicine Reports·Lysann KroschwaldAndrea Bauer
Dec 29, 2020·Expert Opinion on Drug Safety·Haochen JiangPeihua Luo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.